Lebrikizumab provides stable skin response with no or minimal fluctuations for up to 2 years in patients with atopic dermatitis
A majority of lebrikizumab Week 16 responders maintained stable efficacy in measures of skin and itch during 2 years of treatment.
Authors
- J.Q. Del Rosso (ORCID: https://orcid.org/0000-0003-4215-7340)
- Jonathan I. Silverberg (ORCID: https://orcid.org/0000-0003-3686-7805)
- Gaia Gallo
- Marta Casillas (ORCID: https://orcid.org/0000-0002-6339-5279)
- Gil Yosipovitch (ORCID: https://orcid.org/0000-0001-6303-1822)
- Sonja Ständer (ORCID: https://orcid.org/0000-0003-3612-7786)
- Peter Lio (ORCID: https://orcid.org/0000-0001-7600-0152)
- Yuxin Ding (ORCID: https://orcid.org/0000-0001-8968-9147)
- Linda Stein Gold (ORCID: https://orcid.org/0000-0002-2758-1605)
- J.M. Carrascosa (ORCID: https://orcid.org/0000-0003-4266-0771)
- Christian Vestergaard (ORCID: https://orcid.org/0000-0001-6485-3158)
- Andreas Wollenberg (ORCID: https://orcid.org/0000-0003-0177-8722)
- Evangeline Pierce (ORCID: https://orcid.org/0000-0002-8287-2835)
- Helena Agell
- Fan Emily Yang
Institutions
- Northwestern University (US)
- Universitat Autònoma de Barcelona (ES)
- University of Nevada, Las Vegas (US)
- University of Miami (US)
- Henry Ford Health System (US)
- Eli Lilly (United States) (US)
- George Washington University (US)
- University Hospital Augsburg (DE)
- Aarhus University Hospital (DK)
- University Hospital Münster (DE)
- Almirall (Spain) (ES)
- Ludwig-Maximilians-Universität München (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Clinical and Experimental Dermatology
- Published
- 2025-11-06
- DOI
- https://doi.org/10.1093/ced/llaf490
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00